Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Drug Discov Today. 2015 Nov 26;21(6):989–996. doi: 10.1016/j.drudis.2015.11.008

Figure 4.

Figure 4

BDA-366 suppresses lung cancer tumor growth by selectively targeting the BH4 domain of Bcl-2 and Bcl-2-dependent Bax activation. (a) The chemical structure of BDA-366 is shown. (b) BDA-366 binds Bcl-2 selectively as illustrated by the competition fluorescence polarization assay. (c) BDA-366 can induce Bcl-2-dependent Bax activation rather than activate Bax directly. (d) BDA-366 strongly synergizes with RAD001 in vivo. Reproduced, with permission, from [50].